NxStage Medical's (NASDAQ:NXTM) System One Driven by Quality of Life

Citing patients' response to using NxStage Medical's (NASDAQ:NXTM) System One, which is a home dialysis system, Canaccord sees adoption of System One continuing to grow.

Canaccord says, "We reiterate our rating and Best Idea designation on NxStage Medical following our System One patient dinner as it reconfirmed the large unmet clinical need the treatment fills. Quality of life (QoL) improvement seems to be the biggest driver of adoption and patient retention. We continue to believe that with the improved reimbursement landscape in 2011 and clinical data support, there is an increasing awareness and focus on performing dialysis in the home, which bodes well for the adoption of System One."

Canaccord Genuity maintains a "Buy" rating on NxStage Medical (NXTM), which closed Monday at $24.56, gaining $0.44, or 1.82 percent. Canaccord has a price target on $29 on NxStage, boosting it from $27.